More than 10% of cancer patients in the U.S. die not from their cancer but from cardiovascular complications, according to a study published in the European Heart Journal Nov. 25.

A study published in the November issue of the Journal of the American College of Cardiology confirms that patients defined as “very high risk” for future ASCVD events by updated society guidelines do indeed carry a much higher risk of adverse outcomes down the road.

Nearly 93% of the U.S. population lives in a hospital referral region with at least one medical center that performs 25 or more mitral valve repairs or replacements each year, according to work published in JAMA Cardiology—but MVRR centers continue to suffer from significant geographical and patient-level disparities.

A group of researchers in the U.K. reported this week that even slight increases in a person’s cardiac troponin levels predict adverse outcomes—including early death—in patients of all ages.

A study presented at the American Heart Association’s Scientific Sessions in Philadelphia this November found that heart patients who practiced routine intermittent fasting over a period of four and a half years were ultimately healthier than those who didn’t.

People trained to perform CPR with a virtual reality tool were able to achieve comparable chest compression rates as those trained face-to-face in a recent randomized study—but the VR approach still has a long way to go.

Legal loopholes in the 510(k) clearance process mean countless faulty BP devices can make it to pharmacy shelves without proper testing, leading to confusion among consumers and healthcare providers alike, according to a news story from the American Medical Association.

Primary results from the GALILEO trial, presented at the American Heart Association’s annual meeting this November, suggest patients undergoing TAVR with no ongoing indication for oral anticoagulation benefit more from an antiplatelet-based treatment approach than a rivaroxaban-based approach.